Examining the link between price regulation and pharmaceutical R&D investment

Health Economics

Volumn 14, Issue 1, 2005, Pages 1-16

  Vernon, John A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Pharmaceutical innovation; Pharmaceutical profitability; Pharmaceuticals; Price regulation; R D investment

Indexed keywords

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; ECONOMIC EVALUATION; EMPIRICISM; HEALTH ECONOMICS; HUMAN; INVESTMENT; MATHEMATICAL COMPUTING; PHARMACEUTICAL CARE; POLICY; PREDICTION; PRIORITY JOURNAL; PROFIT; PROSPECTIVE PRICING; QUANTITATIVE ANALYSIS; SOCIAL WELFARE; THEORETICAL MODEL; UNITED STATES;

COMMERCE; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; MODELS, ECONOMIC; RESEARCH; UNITED STATES;

EID: 12344253089     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.897     Document Type: Article

References (28)

1. Danzon P. Making sense of drug prices. Regulation 2000; 23(1): 56-63.
2. Danzon P. Price Regulation for Pharmaceuticals: Global vs National Interests. The American Enterprise Institute Press: 1997.
3. Grabowski HG. The determinants of industrial research and development: a study of the chemical, drug, and petroleum industries. J Political Econ 1968; 76: 292-306.
4. Grabowski HG, Vernon JM. The determinants of R&D expenditures in the pharmaceutical industry. In Drugs and Health, Helms R (ed. . AEI Press: Washington, DC, 1981.
5. Grabowski HG, Vernon JM. A new look at the risks and returns to pharmaceutical R&D. Manage Sci 1990; 36(7): 804-821.
6. Grabowski HG, Vernon JM. The determinants of pharmaceutical research and development expenditures. J Evol Econ 2000; 10: 201-215.
7. Modigliani F, Miller M. The cost of capital, corporation finance and the theory of investment. Am Econ Rev 1958; 48: 261-297.
8. Fazzari S, Hubbard G, Petersen, B. Financing constraints and corporate investment. Brookings Paper on Economic Activity, 1988.
9. Hall BH. Investment and research and development at the firm level: does the source of financing matter? NBER Working Papers, Working Paper No. 4096, NBER, 1992.
10. Hubbard G. Capital market imperfections and investment. J Econ Literature 1998; XXXVI: 193-225.
11. Henderson R, Cockburn I. Scale, scope and sṕillovers: the determinants of research productivity in drug discovery. RAND J Econ 1996; 27: 32-59.
12. Sykes R. The Pharmaceutical Industry in the New Millennium: Capturing the Scientific Promise. Center for Medicines Research International Publications: Carshalton, Surrey, UK, 1997.
13. Vernon J. Drug research and price controls. Regulation 2003a; 25(4).
14. Vernon J. The relationship between price regulation and pharmaceutical profit margins. Appl Econ Lett 2003b; 10: 467-470.
15. Penrose ET. The Theory of the Growth of the Firm. Wiley: New York, 1959.
16. Barney J. Firm resources and sustained competitive advantage. J Manage 1991; 17(1): 99-120.
17. Lichtenberg FR. Probing the link between gross profitability and R&D spending. Health Affairs 2001; 20: 221-222.
18. Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 2001; 20: 216-220.
19. Scherer FM. Pricing, profits, and technological progress in the pharmaceutical industry. J Econ Perspectives 1993; 7(3 : 97-115.
20. Grabowski HG. Health Reform and Pharmaceutical Innovation. AEI Press: Washington, DC, 1994.
21. Helms R. Commentary. In Competitive Strategies in the Pharmaceutical Industry, Helms R (ed.). AEI Press: Washington, DC, 1996.
22. Green D. Is price regulation necessary: a summary of arguments. Pharmacoeconomics 1998; 14(Sup 1): 137-142.
23. Berndt E. International comparaisons of pharmaceutical prices: what do we know, and what does it mean? J Health Econ 2000; 19(2): 283-287.
24. Hasio C. Analysis of Panel Data. Cambridge University Press: Cambridge, 1986; 41.
25. Hausman J. Specification tests in econometrics. Econometrica 1978; 46(6): 1251-1271.
26. Danzon P, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs. University of Pennsylvania Working Paper, 2003.
27. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22 151-185.
28. Arrow K. Economic welfare and the allocation of resources for invention. In NBER The Rate and Direction of Inventive Activity. Princeton University Press: Princeton, NJ, 1962.